Weight-loss drug could help address nighttime sleep disruptions for millions

An experimental obesity drug significantly reduced breathing interruptions and other symptoms of obstructive sleep disorder in two clinical trials, according to new research published in The New England Journal of Medicine.

Obstructive sleep apnea (OSA) affects more than 50 million Americans, and about 80% of cases are undiagnosed, according to the National Sleep Foundation.

The study examined whether retatrutide, an investigational weight-loss drug from Eli Lilly, could help treat OSA in adults who were overweight or obese.